1249 studies found for:    HER2
Show Display Options
Rank Status Study
1 Recruiting Treatment of Chemotherapy Refractory Human Epidermalgrowth Factor Receptor-2( HER-2) Positive Advanced Solid Tumors
Conditions: Advanced HER-2 Positive Solid Tumors;   Chemotherapy Refactory;   HER-2 Antibody Inhibitor Therapy Refactory
Intervention: Biological: CART-HER-2
2 Recruiting Her2 and TGFBeta CTLs in Treatment of Her2 Positive Malignancy
Condition: HER2 Positive Malignancies
Intervention: Genetic: TGFBeta resistant HER2/EBV-CTLs
3 Withdrawn Ex Vivo-Expanded HER2-Specific T Cells and Cyclophosphamide After Vaccine Therapy in Treating Patients With HER2-Positive Stage IV Breast Cancer
Conditions: HER2-positive Breast Cancer;   Male Breast Cancer;   Stage IV Breast Cancer
Interventions: Biological: HER-2/neu peptide vaccine;   Drug: cyclophosphamide;   Biological: ex vivo-expanded HER2-specific T cells;   Other: laboratory biomarker analysis;   Other: flow cytometry;   Other: immunoenzyme technique
4 Active, not recruiting Vaccine Therapy in Combination With Rintatolimod and/or Sargramostim in Treating Patients With Stage II-IV HER2-Positive Breast Cancer
Conditions: HER2-positive Breast Cancer;   Male Breast Cancer;   Recurrent Breast Cancer;   Stage II Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer;   Stage IV Breast Cancer
Interventions: Biological: HER-2/neu peptide vaccine;   Biological: sargramostim;   Drug: rintatolimod;   Other: laboratory biomarker analysis
5 Active, not recruiting Vaccine Therapy in Treating Patients With Previously Treated Stage II-III HER2-Positive Breast Cancer
Conditions: HER2-positive Breast Cancer;   Male Breast Cancer;   Stage II Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer
Interventions: Biological: HER-2/neu peptide vaccine;   Other: laboratory biomarker analysis
6 Completed Addition of Carboplatin to Neoadjuvant Therapy for Triple-negative and HER2-positive Early Breast Cancer
Conditions: Tubular Breast Cancer Stage II;   Mucinous Breast Cancer Stage II;   Breast Cancer Female NOS;   Invasive Ductal Breast Cancer;   Tubular Breast Cancer Stage III;   HER-2 Positive Breast Cancer;   Inflammatory Breast Cancer Stage IV;   Inflammatory Breast Cancer
Interventions: Drug: Carboplatin;   Drug: background treatment according to standards fpr triple negative and Her2pos breast cancer patients
7 Not yet recruiting HER2 Positive CTC in Advanced Gastric Cancer
Condition: HER2 Positive Advanced Gastric Cancer
Intervention: Device: Cell Search® CTC epithelial kit
8 Active, not recruiting Vaccine Therapy in Treating Patients Receiving Trastuzumab For HER2-Positive Stage IIIB-IV Breast Cancer
Conditions: HER2-positive Breast Cancer;   Male Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer;   Stage IV Breast Cancer
Interventions: Biological: HER-2/neu intracellular domain protein;   Procedure: leukapheresis;   Other: laboratory biomarker analysis;   Biological: sargramostim;   Other: immunologic technique;   Biological: synthetic tumor-associated peptide vaccine therapy
9 Recruiting Her2 Chimeric Antigen Receptor Expressing T Cells in Advanced Sarcoma
Condition: Sarcoma
Intervention: Genetic: Autologous HER2-specific T cells
10 Active, not recruiting Cyclophosphamide or Denileukin Diftitox Followed By Expanding a Patient's Own T Cells in the Laboratory in Treating Patients With HER-2/Neu Overexpressing Metastatic Breast Cancer, Ovarian Cancer, or Non-Small Cell Lung Cancer Previously Treated With HER-2/Neu Vaccine
Conditions: HER2-positive Breast Cancer;   Recurrent Breast Cancer;   Recurrent Non-small Cell Lung Cancer;   Recurrent Ovarian Epithelial Cancer;   Recurrent Ovarian Germ Cell Tumor;   Stage IV Breast Cancer;   Stage IV Non-small Cell Lung Cancer;   Stage IV Ovarian Epithelial Cancer;   Stage IV Ovarian Germ Cell Tumor
Interventions: Drug: ex vivo-expanded HER2-specific T cells;   Drug: cyclophosphamide;   Biological: denileukin diftitox;   Other: flow cytometry;   Other: immunoenzyme technique
11 Recruiting HER2 PET Imaging in Breast Cancer Patients Using [68GA]ABY-025
Condition: HER2-positive Breast Cancer
Intervention: Other: Radiolabeled  [68Ga]ABY-025
12 Completed
Has Results
Trastuzumab, Ixabepilone, and Carboplatin in Treating Patients With HER2/Neu-Positive Metastatic Breast Cancer
Conditions: HER2-positive Breast Cancer;   Male Breast Cancer;   Recurrent Breast Cancer;   Stage IV Breast Cancer
Interventions: Biological: trastuzumab;   Drug: ixabepilone;   Drug: carboplatin;   Other: laboratory biomarker analysis
13 Recruiting Ad/HER2/Neu Dendritic Cell Cancer Vaccine Testing
Conditions: Breast Neoplasms;   Breast Cancer;   Adenocarcinomas;   Metastatic Solid Tumors Characterized by HER2/Neu Expression
Intervention: Biological: Autologous Ad HER2 dendritic cell vaccine
14 Recruiting Vaccine Therapy and Trastuzumab With or Without Polysaccharide-K in Treating Patients With Stage IV HER2 Positive Breast Cancer
Conditions: HER2-positive Breast Cancer;   Male Breast Cancer;   Recurrent Breast Cancer;   Stage IV Breast Cancer
Interventions: Biological: HER-2/neu intracellular domain protein;   Biological: trastuzumab;   Other: placebo;   Biological: polysaccharide-K;   Other: laboratory biomarker analysis
15 Recruiting Carboplatin+Nab-paclitaxel, Plus Trastuzumab (HER2+) or Bevacizumab (HER2-) in the Neoadjuvant Setting
Conditions: Breast Cancer;   HER2-negative Breast Cancer;   HER2-positive Breast Cancer;   Recurrent Breast Cancer;   Stage IA Breast Cancer;   Stage IB Breast Cancer;   Stage II Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer
Interventions: Drug: Carboplatin;   Drug: paclitaxel albumin-stabilized nanoparticle formulation;   Drug: bevacizumab;   Drug: trastuzumab;   Procedure: magnetic resonance imaging;   Procedure: therapeutic conventional surgery
16 Active, not recruiting Vaccine Therapy in Treating Patients With Stage IV Breast Cancer
Conditions: HER2-positive Breast Cancer;   Male Breast Cancer;   Recurrent Breast Cancer;   Stage IV Breast Cancer
Interventions: Biological: HER-2/neu peptide vaccine;   Procedure: leukapheresis;   Biological: ex vivo-expanded HER2-specific T cells;   Drug: cyclophosphamide;   Biological: sargramostim;   Other: laboratory biomarker analysis
17 Recruiting Pilot Imaging Study With 89Zr-Trastuzumab in HER2-positive Metastatic Breast Cancer Patients
Conditions: Breast Neoplasms;   Secondary;   HER2 Positive Carcinoma of Breast
Intervention: Drug: Zr89-trastuzumab
18 Recruiting Vaccine Therapy in Treating Patients With Stage IV Hormone Receptor Positive Breast Cancer
Conditions: HER2-positive Breast Cancer;   Male Breast Cancer;   Recurrent Breast Cancer;   Stage IV Breast Cancer
Interventions: Biological: HER-2/neu peptide vaccine;   Other: laboratory biomarker analysis
19 Recruiting Cardiac Safety Study in Patients With HER2 + Breast Cancer
Conditions: HER2 Positive Breast Cancer;   Left Ventricular Function Systolic Dysfunction
Intervention: Drug: Trastuzumab, Pertuzumab, Ado-trastuzumab emtansine
20 Recruiting Validity of HER2-amplified Circulating Tumor Cells to Select Metastatic Bresat Cancer Considered HER2-negative for Trastuzumab-emtansine (T-DM1) Treatment.
Condition: Patients With Metastatic Breast Cancer Considered HER2 Negative on Primary Tumor.
Intervention: Drug: Trastuzumab - Emtansine

Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results
Indicates status has not been verified in more than two years